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Abstract
Skin and soft-tissue infections (SSTIs) encompass a variety of pathological conditions that involve the skin and underlying
subcutaneous tissue, fascia, or muscle, ranging from simple superficial infections to severe necrotizing infections. SSTIs are
a frequent clinical problem in surgical departments. In order to clarify key issues in the management of SSTIs, a task force
of experts met in Bertinoro, Italy, on June 28, 2018, for a specialist multidisciplinary consensus conference under the
auspices of the World Society of Emergency Surgery (WSES) and the Surgical Infection Society Europe (SIS-E). The
multifaceted nature of these infections has led to a collaboration among general and emergency surgeons, intensivists,
and infectious disease specialists, who have shared these clinical practice recommendations.
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Introduction
Skin and soft-tissue infections (SSTIs) encompass a var-
iety of pathological conditions that involve the skin and
underlying subcutaneous tissue, fascia, or muscle, ran-
ging from simple superficial infections to severe necro-
tizing infections. SSTIs may affect any part of the body
and are a frequent clinical problem in surgical depart-
ments [1, 2].
Successful management of patients with severe SSTIs
involves prompt recognition, appropriate antibiotic ther-
apy, timely surgical debridement or drainage, and resus-
citation when required.
Several critical issues have been debated in the man-
agement of these patients. In order to clarify these major
issues in the management of SSTIs, a panel of experts
met in Bertinoro, Italy, on June 28, 2018, for a specialist
multidisciplinary consensus conference under the aus-
pices of the World Society of Emergency Surgery
(WSES) and the Surgical Infection Society Europe
(SIS-E).
During the consensus conference, 17 panelists pre-
sented the statements developed for each of the main
questions regarding the diagnosis and management of
SSTIs. An agreement on all the statements was
reached.
The expert panel met via email to prepare and revise the
consensus paper resulting from the meeting. The manu-
script was successively reviewed by all members and ultim-
ately revised as the present manuscript. This document
represents the executive summary of the consensus confer-
ence which outlines clinical recommendations based on the
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Grading of Recommendations Assessment, Development,
and Evaluation (GRADE) hierarchy criteria summarized in
Table 1 [3].
How should SSTIs be classified?
The term “skin and soft-tissue infections” describes a
wide heterogeneity of clinical conditions. We recom-
mend that the necrotizing or non-necrotizing charac-
ter of the infection, the anatomical extension, the
characteristics of the infection (purulent or not puru-
lent), and the clinical condition of the patient should
be always assessed independently to classify patients
with soft-tissue infections (recommendation 1C).
SSTIs encompass a variety of pathological conditions
involving the skin and underlying subcutaneous tissue,
fascia, or muscle and ranging from simple superficial in-
fections to severe necrotizing infections.
Various classification systems have been used to de-
scribe SSTIs including variables such as anatomic loca-
tion, causative pathogen(s), rate of progression, depth of
infection, and severity of clinical presentation.
In 1998, the US Food and Drug Administration (FDA)
classified SSTIs into two broad categories for the pur-
pose of clinical trials evaluating new antimicrobials for
their treatment: uncomplicated and complicated. Un-
complicated SSTIs included superficial infections such
as cellulitis, simple abscesses, impetigo, and furuncles
and required antibiotics or surgical incision for drainage
of abscess alone. In contrast, complicated SSTIs in-
cluded deep soft-tissue infections such as necrotizing in-
fections, infected ulcers, infected burns, and major
abscesses which required significant surgical interven-
tion with drainage and debridement [4].
The terms “complicated” and “uncomplicated” persist
and can be useful in describing SSTIs as reported by
Napolitano [5].
Uncomplicated SSTIs carry low risk for life- or
limb-threatening infection unless they are improperly
treated. Patients who have uncomplicated SSTIs can be
treated with either empiric antibiotic therapy according
to the most probable pathogen and local resistance pat-
terns in impetigo, erysipelas, or mild cellulitis with
drainage and debridement or simple surgical drainage in
skin abscess.
Complicated SSTIs are associated with high risk for
life-threatening infection. In patients who have compli-
cated SSTIs, it is of paramount importance to initiate
appropriate and adequate broad-spectrum initial empiric
antibiotic therapy and to consider the need for surgical
intervention for drainage and/or debridement.
In 2003, Eron et al. [6] classified SSTIs according to
the severity of local and systemic signs and the presence
or absence of comorbid conditions in patients presenting
in the outpatient setting to guide the clinical
management, treatment, and admission decisions. In this
classification system, SSTIs were divided in four classes:
Class 1: patients with SSTI, but no signs or symptoms
of systemic toxicity or co-morbidities.
Class 2: patients are either systemically unwell with
stable co-morbidities or are systemically well, but have
a comorbidity (e.g., diabetes, obesity) that may compli-
cate or delay resolution.
Class 3: patients appear toxic and unwell (fever,
tachycardia, tachypnoea, and/or hypotension).
Class 4: patients have sepsis syndrome and life-
threatening infection; for example necrotizing fasciitis.
SSTIs may be also classified according to the anatom-
ical tissue layers involved [7]. Superficial infections such
as erysipelas, impetigo, folliculitis, furuncles, and car-
buncles are located at the epidermal and dermal layer,
while cellulitis is located in the dermis and subcutaneous
tissue. Deep infections extend below the dermis and may
involve the subcutaneous tissue, fascial planes, or mus-
cular compartments presenting as complex abscesses,
fasciitis, or myonecrosis.
Complicated SSTIs may also be classified as
non-necrotizing or necrotizing infections. Necrotizing
infections most commonly involve the muscular fascial
layers but may also involve the dermal, subcutaneous,
and muscle layers and warrant prompt, aggressive surgi-
cal debridement.
In 2014, the Infectious Diseases Society of America
(IDSA) updated practice guidelines for the diagnosis and
management of skin and soft-tissue infections [8]. The
guidelines divided infections by purulent and
non-purulent, severity (mild, moderate, and severe), and
tissue necrosis (necrotizing versus non-necrotizing).
Recently, the US FDA has introduced the new defin-
ition of acute bacterial skin and skin-structure infection
(ABSSSI) to more closely define complicated soft-tissue
infection for the purposes of registration trials. ABSSSIs
include cellulitis/erysipelas, wound infections, and major
cutaneous abscesses. Thus, an ABSSSI is defined as a
bacterial infection of the skin with a lesion size area of
≥ 75 cm2 (lesion size measured by the area of redness,
edema, or induration) [9].
In 2015, the WSES published its guidelines for man-
agement of SSTIs [10] proposing a new definition divid-
ing SSTIs in three main groups: surgical site infections
(SSIs), non-necrotizing SSTIs, and necrotizing SSTIs.
SSIs are classified into two subgroups: incisional and
organ and organ/space. The incisional SSIs are further
divided into superficial (skin and subcutaneous tissue)
and deep (deep soft-tissue muscle and fascia). Organ
and organ/space infections are not truly soft-tissue infec-
tions. Non-necrotizing SSTIs including erysipelas,
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impetigo, folliculitis, simple abscess, and complex ab-
scess may be treated by antibiotics or drainage alone.
Necrotizing SSTIs (cellulitis, fasciitis, myositis, Fournier’s
gangrene) require surgical intervention including drainage
and debridement of necrotic tissue in addition to antibiotic
therapy.
Several authors and organizations have proposed clas-
sification schemes for SSTIs based on such variables as
anatomic location, rate of progression, depth of exten-
sion, and clinical presentation or severity. Each has key
limitations both in assisting clinical management and in
providing guidance for developing new therapeutic
agents.
The consensus concluded that the necrotizing or
non-necrotizing character of the infection, the anatom-
ical extension, the characteristics of the infection (puru-
lent or non-purulent), and the clinical conditions of the
patient should be always assessed independently to clas-
sify patients with soft-tissue infections.
What is new in the prevention of SSIs? What are
the principles of SSI prevention?
Recent global guidelines for the prevention of SSIs
can support healthcare workers to develop or
strengthen infection prevention and control pro-
grams, with a focus on surgical safety, as well as
antimicrobial resistance action plans. We recom-
mend that all healthcare workers adopt these
evidence-based recommendations in their clinical
practice (recommendation 1C).
SSIs are the most common healthcare-associated in-
fections among surgical patients. It is obviously import-
ant to improve patient safety by reducing the occurrence
of SSIs. Preventing SSIs is a global priority. Bacteria are
becoming increasingly resistant to antibiotics, making
SSI prevention even more important nowadays.
SSIs are a major clinical problem in terms of morbid-
ity, mortality, length of hospital stay, and overall direct
and not-direct costs worldwide. Despite progress in pre-
vention knowledge, SSIs remain one of the most com-
mon adverse events in hospitals. SSI prevention is
complex and requires the integration of a range of mea-
sures before, during, and after surgery.
Both the World Health Organization (WHO) [11, 12]
and the Centers for Disease Control and Prevention
(CDC) [13] have recently published guidelines for the
prevention of SSIs. The 2016 WHO Global guidelines
for the prevention of surgical site infection [11, 12] are
evidence-based including systematic reviews presenting
additional information in support of actions to improve
practice.
The guidelines include 13 recommendations for the
pre-operative period, and 16 for preventing infections
during and after surgery. They range from simple
precautions such as ensuring that patients bathe or
shower before surgery, appropriate way for surgical
teams to clean their hands, guidance on when to use
prophylactic antibiotics, which disinfectants to use be-
fore incision, and which sutures to use.
The proposed recommendations are as follows:
 “Strong” – Expert panel was confident that benefits
outweighed risks, considered to be adaptable for
implementation in most (if not all) situations, and
patients should receive intervention as course of
action.
 “Conditional” – Expert panel considered that
benefits of intervention probably outweighed the
risks; a more structured decision-making process
should be undertaken, based on stakeholder consult-
ation and involvement of patients and healthcare
professionals.
Importantly, the guidelines recommend that antibiotic
prophylaxis should be used to prevent infections before
and during surgery only. Antibiotics should not be used
after surgery, as is often done. Antibiotic prophylaxis
should be administered for operative procedures that
have a high rate of postoperative surgical site infection,
or when foreign materials are implanted. Antibiotic
prophylaxis should be administered within 120 min prior
to the incision. However, administration of the first dose
of antibiotics is dependent on its pharmacological char-
acteristics. Underlying patient factors may also affect
drug disposition (e.g., malnourishment, obesity, cachexia,
and renal disease with protein loss may result in sub-
optimal antibiotic exposure through increased antibiotic
clearance in the presence of normal or augmented renal
function). Additional antibiotic doses should be adminis-
tered intraoperatively for procedures > 2–4 h (typically
where duration exceeds two half-lives of the antibiotic).
There is no evidence to support the use of postoperative
antibiotic prophylaxis. The key evidence-based recom-
mendations outlined in these guidelines should be
adopted by all healthcare staff that care for surgical pa-
tients throughout all stages of that patient’s surgical
care.
What is the best treatment of incisional SSIs?
When are antibiotics needed?
Incisional SSIs require prompt and wide opening of
the surgical incision. We recommend antibiotic ther-
apy for incisional SSIs with any Systemic Inflammatory
Response Syndrome criteria or signs of organ failure
such as hypotension, oliguria, decreased mental alert-
ness, or in immunocompromised patients (recommen-
dation 1C).
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SSIs are generally classified according to CDC criteria
[14]. SSIs are classified as superficial incisional infection,
deep incisional infection, and organ space infection.
Superficial incisional infections are the most common
type of SSIs. Deep incisional and organ/space are the
types of SSIs that cause the most morbidity. Organ space
infections are not genuine soft-tissue infections.
Incisional SSIs are the results of several factors [15]. All
surgical wounds are contaminated by bacteria, but only a
minority actually develops clinical infection. Colonization
occurs when the bacteria begin to replicate and adhere to
the wound site. If the host’s immune response is not suffi-
cient to eliminate or overcome the effects of the bacteria,
infection occurs [16]. In most patients, infection does not
develop because host defenses are efficient to eliminate
colonizers at the surgical site; however, in some patients,
host defenses fail to protect them from SSIs. It is well
known that surgical trauma increases inflammatory re-
sponse and counter-regulatory mechanisms. Such regula-
tory mechanism can decrease postoperative immune
response, promoting SSIs.
The pathogens isolated from infections differ, primarily
depending on the type of surgical procedure. In
clean-contaminated or contaminated surgical proce-
dures, the aerobic and anaerobic pathogens of the nor-
mal endogenous microflora of the surgically resected
organ are the most frequently isolated pathogens. In
clean surgical procedures, in which the gastrointestinal,
gynecologic, and respiratory tracts have not been en-
tered, Staphylococcus aureus from the exogenous envir-
onment or the patient’s skin flora is the usual cause of
infection. Nevertheless, in some specific body areas such
as the groin skin could also be colonized by enteric flora.
Moreover, it is possible that procedures such as hip
prosthesis or vascular bypass, performed on this ana-
tomical region, might eventually be infected by
Gram-negative bacteria.
Sganga et al. [17] have recently reported that the risk
factors associated with SSIs caused by Methicillin-resis-
tant Staphylococcus aureus (MRSA), identified using the
Delphi method were patients from long-stay care facil-
ities, a hospitalization within the preceding 30 days,
Charlson score > 5 points, chronic obstructive pulmon-
ary disease and thoracic surgery, antibiotic therapy with
beta-lactams (especially cephalosporins), and carbapen-
ems and/or quinolones in the preceding 30 days, age 75
years or older, current duration of hospitalization > 16
days, and surgery with prosthesis implantation.
An important determinant of SSI is the integrity of
host defenses. Important host factors include the follow-
ing [18]: age, malnutrition status, diabetes, smoking,
obesity, colonization with microorganisms, length of
hospital stay or previous hospitalization, shock and hyp-
oxemia, and hypothermia.
It is a common practice to cover surgical wounds with
a dressing. The dressing acts as a physical barrier to pro-
tect the wound from contamination from the external
environment until the wound becomes impermeable to
microorganisms.
Postoperative care bundles recommend that surgical
dressings be kept undisturbed for a minimum of 48 h
after surgery unless leakage occurs. However, there are
currently no specific recommendations or guidelines re-
garding the type of surgical dressing [19].
The diagnosis of incisional surgical site infection is
clinical. Symptoms may include localized erythema, in-
duration, warmth, and pain at the incision site. Purulent
wound drainage and separation of the wound may occur.
Most patients have systemic signs of infection such as
fever and leukocytosis. Information on the microbio-
logical species present in the wound is useful for deter-
mining antibiotic choice and predicting response to
treatment.
An incisional SSI should be sampled if there is a clin-
ical suspicion of infection. Lack of standardized criteria
for diagnostic microbiology of SSIs present a challenge
to monitor the global epidemiology of surgical site infec-
tion. Emergence of antibiotic resistance has made the
management of SSIs difficult. Moreover, rapidly emer-
ging nosocomial pathogens and the problem of multi-
drug resistance necessitates periodic review of isolation
patterns and their sensitivity.
Adequate treatment of incisional SSIs should always
include:
 Surgical incision and drainage of abscess.
 Debridement of necrotic tissue, if present.
 Appropriate wound care.
 Resuscitation to improve perfusion when sepsis is
present.
 Adequate empiric antibiotic therapy when indicated.
 De-escalation when antibiogram is available.
Incisional SSIs should always be drained, irrigated, and if
needed, opened and debrided. If fascial disruption is sus-
pected, drainage should always be performed. Percutaneous
drainage, wound irrigation, and negative pressure-assisted
wound management are new and effective options that re-
duce the need for open management of wound infections.
In cases where open management is needed, once the infec-
tion has cleared, the wound can be closed.
Superficial incisional SSIs that have been opened can
usually be managed without antibiotics.
In patients with incisional SSIs with the presence of
any systemic inflammatory response criteria or signs of
organ failure such as hypotension, oliguria, decreased
mental alertness, or in immunocompromised patients,
empiric broad-spectrum antibiotic treatment should be
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started with coverage for Gram-positive cocci and/or the
expected flora at the site of operation. Definitive anti-
biotic treatment is guided by the clinical response of the
patient and, when available, results of gram stain, wound
culture, and antibiogram.
What is the appropriate treatment of superficial
infections (impetigo, erysipelas and cellulitis, and
superficial abscesses)?
We recommend that impetigo, erysipelas, and cellu-
litis should be managed by antibiotics against
Gram-positive bacteria (recommendation 1C).
Empiric therapy for community-acquired MRSA
(CA-MRSA) should be recommended for patients at
risk for CA-MRSA or who do not respond to first
line therapy (recommendation 1C).
Incision and drainage is the primary treatment for
simple abscesses or boils. We recommend not to use
antibiotics for simple abscesses or boils (recommenda-
tion 1C).
Superficial infections encompass either superficial
spreading infection and inflammation within the epider-
mis and dermis that may be treated with antibiotics
alone or a well-circumscribed abscess that may be
treated by drainage alone.
Physical examination usually reveals erythema, tender-
ness, and induration. The majority of superficial SSTIs
are caused by Gram-positive bacteria, particularly
streptococci and S. aureus. The three common presenta-
tions of superficial infections consist of impetigo, erysip-
elas, and cellulitis. They are managed by antibiotic
therapy against Gram-positive bacteria.
Impetigo is a highly contagious bacterial infection of
the superficial layers of the epidermis. Impetigo predom-
inantly affects children, and it is one of the most com-
mon SSTI in children worldwide [20]. It is characterized
by discrete purulent lesions nearly always caused by
β-hemolytic Streptococcus spp. and/or S. aureus. More-
over, of particular concern is the rising role of
CA-MRSA as impetigo’s etiological agent [21–23].
Erysipelas is a fiery red, tender, painful plaque with
well-demarcated edges and is commonly caused by
streptococcal species, usually Staphylococcus pyogenes. S.
aureus rarely causes erysipelas [24]. Streptococci are the
primary cause of erysipelas. Most facial infections are at-
tributed to group A Streptococcus (GAS), with an in-
creasing percentage of lower extremity infections being
caused by non-GAS. The role of S. aureus, and specific-
ally MRSA, remains controversial [25].
Cellulitis is an acute bacterial infection of the dermis
and the subcutaneous tissue that most commonly affects
the lower extremities, although it can affect other areas.
It causes local signs of inflammation, such as warmth,
erythema, pain, lymphangitis, and frequently systemic
upset with fever and raised white blood cell count [26].
As already reported in a previous paragraph, cellulitis
has been recently classified as an ABSSSI together with
erysipelas, SSIs, and major abscesses.
In a large European multicenter study, Garau et al.
[27] analyzed a population of patients diagnosed with
complicated SSTI hospitalized between December 2010
and January 2011 reporting that cellulitis was the most
frequent diagnosis accounting for 59.1% of the total.
Streptococci cause diffuse, rapidly spreading infection;
staphylococcal cellulitis is typically more localized.
Treatment should begin promptly with agents effective
against the typical Gram-positive pathogens, especially
streptococci. If the cellulitis is very early and mild and no sig-
nificant co-morbidities are present, oral beta-lactams might
be sufficient in areas where CA-MRSA is not prevalent.
Other available options are macrolides and lincosamides;
however, resistance to erythromycin and clindamycin are in-
creasing. Fluoroquinolones have been approved for the treat-
ment of most uncomplicated cellulitis but are not adequate
for treatment of MRSA infections. For more severe infec-
tions, parenteral route is the first choice.
If MRSA is suspected (both hospital acquired MRSA
[HA-MRSA] and CA-MRSA), glycopeptides and newer
antimicrobials are the best options [25, 28, 29]. For a
simple superficial abscess or boil, incision and drainage
is the primary treatment, and antibiotics are not needed.
To be considered a simple abscess, induration and ery-
thema should be limited only to a defined area of the ab-
scess and should not extend beyond its borders.
Additionally, simple abscesses do not extend into deeper
tissues or have multiloculated extension. Cutaneous ab-
scesses are typically caused by bacteria that represent
the normal regional skin flora of the involved area [30].
What is the appropriate treatment of complex
abscesses (perianal and perirectal, and abscesses
in intravenous drug injection sites)?
Complex skin and subcutaneous abscesses are typic-
ally well circumscribed and respond to incision and
drainage. We recommend antibiotic therapy if sys-
temic signs of infection are present, in immunocom-
promised patients, if source control is incomplete or
in cases of abscess with significant cellulitis (recom-
mendation 1C).
We recommend empiric broad-spectrum antibiotic
therapy with coverage of Gram-positive, Gram-negative,
and anaerobic bacteria (recommendation 1C).
Common sites of origin of complex abscesses may be
perineal or perianal, perirectal, and abscesses at intra-
venous drug injection sites. Complicated skin and sub-
cutaneous abscesses are typically well circumscribed and
respond to incision and drainage with adjuvant antibiotic
therapy.
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Perianal and perirectal abscesses originate most often
from an obstructed anal crypt gland, with the resultant
pus collecting in the subcutaneous tissue, intersphinc-
teric plane, or beyond (ischiorectal space or supralevator
space) where various types of anorectal abscesses form.
Once diagnosed, anorectal abscesses should be promptly
drained surgically. An undrained anorectal abscess can
continue to expand into adjacent spaces as well as pro-
gress to generalized systemic infection. Anorectal ab-
scess occurs more often in males than females. Most
patients present between the ages of 20 to 60 with the
mean age of 40 in both sexes [31].
The diagnosis of anorectal abscess is usually based on
the patient’s history and physical examination. The
most common symptom of anorectal abscess is pain.
As such, it has to be differentiated from other causes of
anal pain including anal fissure, thrombosed hemor-
rhoids, levator spasm, sexually transmitted diseases,
proctitis, and cancer. Low (intersphincteric, perianal,
and ischiorectal) abscesses are usually associated with
swelling, cellulites, and exquisite tenderness, but few
systemic symptoms. High (submucosal, supralevator)
abscesses may have few local symptoms, but significant
systemic symptoms. Deeper abscesses, such as those
that form in the supralevator or high ischiorectal space,
may also present with pain referred to the perineum,
low back, or buttocks.
The goal of surgical therapy of an abscess is to drain
the abscess expeditiously, identify a fistula tract, and ei-
ther proceed with primary fistulotomy to prevent recur-
rence or place a draining seton for future consideration.
A large abscess should be drained with multiple coun-
ter incisions rather than a long incision, which will cre-
ate a step-off deformity and delay wound healing.
Complicated abscesses may involve a variety of patho-
gens and are frequently polymicrobial in origin.
Although most cases can be managed by incision
and drainage, abscesses in injecting drug users
require special considerations as compared to
soft-tissue infections, which are not caused by intra-
venous drug abuse [32–35]. There are two main
sources of organisms: the injecting drug users them-
selves (their oropharynx, skin, or feces), and the en-
vironment. Contamination may occur when the user
prepares or injects the drug, uses shared needles, or
re-uses injection paraphernalia. Manufacturing and
handling of injectable drugs may be far from hy-
gienic rules [36]. Persistent signs of systemic infec-
tion require evaluation for the presence of
endocarditis. Foreign bodies, such as broken needles,
should be ruled out by radiography, and duplex son-
ography should be performed to identify the pres-
ence of vascular complications [37]. Viral (HIV,
HCV, HBV) acute or chronic infections should be
always ruled out. Broad-spectrum antibiotics effective
against aerobic and anaerobic organisms should be
administered in patients with these infections.
Broad-spectrum agents with coverage of Gram-positive,
Gram-negative, and anaerobic pathogens may be re-
quired depending on the clinical setting. Given the high
frequency of MRSA in some areas, this pathogen
should be empirically covered if it is suspected, but no
randomized studies are available for the treatment of
SSTI specifically caused by CA-MRSA [1].
What is the appropriate treatment of infections
developing in damaged skin (burn wounds,
animal and human bites, and pressure ulcers)?
Irrigation of the wound and debridement of necrotic
tissue are the most important factors in the preven-
tion of infection and can substantially decrease the
incidence of invasive wound infection. Antibiotic
prophylaxis is not generally recommended (recom-
mendation 1C).
For patients with systemic signs of infection, com-
promised immune status, severe comorbidities, associ-
ated severe cellulitis, severe and deep wounds, a
broad-spectrum antibiotic effective against aerobic,
and anaerobic organisms is always required (recom-
mendation 1C).
Infections developing in damaged skin are a heteroge-
neous group that includes bite wounds (animal and hu-
man bites), burn wounds, and pressure ulcers. If
managed incorrectly, these infections can develop into
more complicated soft-tissue infections.
Soft-tissue infection is the most common complication
of animal and human bites. The risk of infection de-
pends on the type of bite, the site of injury, the time
elapsed from the bite until presentation, host factors,
and the management of the wound [38–40]. In general,
10–20% of bite wounds become infected, including 30–
50% of cat bites, 5–25% of dog bites, and 20–25% of hu-
man bites, respectively [41].
The predominant pathogens in these wounds are part
of the normal oral flora of the biting animal, along with
human skin organisms and occasional secondary in-
vaders (e.g., S. aureus and GAS). Along with Staphylo-
coccus ssp. (including MRSA) and Streptococcus ssp.
(including S. pyogenes), the commonly isolated patho-
gens include Pasteurella spp. (Pasteurella multocida,
Pasteurella canis, Pasteurella dagmatis), Capnocytopha-
gia canimorsus, anaerobes (Fusobacterium spp., Prevo-
tella spp., Bacteroides spp., Porphyromonas spp.), and
others. Streptococci can be isolated from 50% of human
bite wounds, S. aureus from 40%, and Eikenella corro-
dens (a Gram-negative facultative anaerobic bacillus)
from 30%. Human bites can transmit HBV, HCV, and
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HIV and post-exposure prophylaxis should be consid-
ered in every case [25].
There is clinical consensus that patients may be di-
vided into low- and high-risk groups depending on the
cause, nature, and location of the injury and on patient
characteristics, but no evidence-based guidelines are cur-
rently available.
Deep irrigation of the wound serves to remove for-
eign bodies and pathogens. Irrigation under pressure is
not recommended, as it may lead to the uncontrolled
spread of bacteria into deeper tissue layers. Surgical
treatment is based on the removal of necrotic tissue
and mechanical reduction of the burden of pathogens.
Universal prophylaxis with antibiotics is not recom-
mended. The comprehensive meta-analyses of Medei-
ros et al. in the Cochrane Database [42] demonstrated
no evidential basis for a reduction of the infection rate
by prophylactic antibiotics, except for bite wounds on
the hands. Despite the poor state of the evidence, most
experts recommend early antibiotic treatment for 3 to
5 days for fresh, deep wounds and wounds in certain
critical bodily areas (hands, feet, areas near joints, face,
genitals), for persons at elevated risk of infection, and
for persons with implants, such as artificial heart valves
[43–45]. Antibiotics should not be given if the patient
presents 24 h or more after the bite and there are no
clinical signs of infection [46].
Significant burn injuries can predispose to infectious
complications. Burn wound infections are one of the
most important and potentially serious complications
that occur in the acute period following injury.
Accurate management of the wound with early exci-
sion of the eschar can substantially decrease the inci-
dence of invasive burn wound infection. Damage to
this barrier following a burn disrupts the innate im-
mune system and increases susceptibility to bacterial
infection. Although burn wound surfaces are sterile
immediately following thermal injury, these wounds
may be colonized with microorganisms. If the pa-
tient’s host defenses and therapeutic measures (such
as excision of necrotic tissue and wound medications)
are inadequate, microorganisms can colonize viable
tissue, and a burn wound infection may occur.
Burn wound infections usually are polymicrobial. They
can be immediately colonized by Gram-positive bacteria
from the patient’s endogenous skin flora or the external
environment. However, they can also be rapidly colo-
nized by Gram-negative bacteria, usually within a week
of the burn injury. Bacterial cultures can aid in the selec-
tion of an appropriate antibiotic, especially in cases of
bacterial drug resistance, but altered pharmacokinetic
parameters in burn patients must be considered and
dosing should be adjusted accordingly to maximize anti-
biotic efficacy [47].
Pressure ulcers are localized areas of tissue necrosis
that tend to develop when soft-tissue is compressed be-
tween a bony prominence and an external surface for a
prolonged period of time. The damage may be relatively
minor, or it may lead to massive destruction of deeper
tissues. The majority of pressure ulcers develop in areas
adjacent to the ischium, sacrum, and greater trochanter.
Pressure ulcers represent a frequent problem especially
in frail elderly patients with chronic co-morbidities [25].
When infection occurs, it is typically polymicrobial and
includes aerobes (S. aureus, Enterococcus spp., Proteus
mirabilis, Escherichia coli, Pseudomonas spp.) and anaer-
obes (Peptococcus spp., Bacteroides fragilis, Clostridium
perfringens) [25].
Combination of surgical and antibiotic interventions
may be required to manage infected decubitus ulcers.
Surgical debridement is necessary to remove necrotic
tissue. Antibiotic therapy should be used for patients
with severe pressure ulcer infections, including those
with spreading cellulitis or patients with systemic signs
of infection. Because such infections usually are polymi-
crobial, therapeutic regimens should be directed against
both Gram-positive and Gram-negative facultative or-
ganisms as well as anaerobic organisms. In many cases
of pressure ulcers, correct wound care management can
largely prevent the occurrence of these infections.
When to administer antibiotics for MRSA in cSSTI?
We recommend to administer antibiotics directed
against MRSA as an adjunct to incision and drainage
based on local epidemiology (area with more than
20% of MRSA in invasive hospital isolates or high
circulation of MRSA in the community), specific risk
factors for MRSA, and clinical conditions (recom-
mendation 1C).
The majority of SSTIs involving healthy skin are
caused by aerobic Gram-positive cocci, specifically S.
aureus and streptococci. Strains of S. aureus and GAS
can produce a variety of toxins that may both potentiate
their virulence and affect the soft tissues and allow inva-
sion of the dermis. SSTIs management has recently be-
come more complicated because of the increasing
prevalence of multidrug-resistant pathogens.
Considerable variation in the resistance rates of S.
aureus to methicillin (or oxacillin) in patients with
SSTIs has been noted between continents, with the
highest rates in North America (35.9%), followed by Latin
America (29.4%) and Europe (22.8%) [48]. Although
MRSA has been usually acquired during exposure in hos-
pitals and other healthcare facilities, there has been a re-
cent increase in MRSA infections presenting in the
community (CA-MRSA) [49]. CA-MRSA strains are gen-
etically and phenotypically distinct from HA-MRSA.
CA-MRSA infections are becoming increasingly common.
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They can have a rapid and devastating course and may
produce the pathogenic Panton–Valentine leucocidin
toxin (PVL), which destroys white blood cells and is an
important virulence factor [50]. They may be susceptible
to a wider range of anti-staphylococcal antibiotics (some
are resistant only to beta-lactams). Populations at in-
creased risk for CA-MRSA are listed below [49]:
 Children < 2 years old.
 Athletes (mainly contact-sport participants).
 Injection drug users.
 Homosexual males.
 Military personnel.
 Inmates of correctional facilities, residential homes,
or shelters.
 Vets, pet owners, and pig farmers.
 Patients with post-flu-like illness and/or severe
pneumonia.
 Patients with concurrent SSTI.
 History of colonization or recent infection with
CA-MRSA.
 History of antibiotic consumption in the previous
year, particularly quinolones, or macrolides.
MRSA poses a significant and enduring problem to
the treatment of infection by such strains. Resistance is
usually conferred by the acquisition of a non-native
gene encoding a penicillin-binding protein (PBP2a),
with significantly lower affinity for beta-lactams. This
resistance allows cell-wall biosynthesis, the target of
beta-lactams, to continue even in the presence of typic-
ally inhibitory concentrations of antibiotic. PBP2a is
encoded by the mecA gene, which is carried on a dis-
tinct mobile genetic element (SCCmec). These genetic
elements contain two required components: the mec
gene complex and the ccr gene complex (which con-
tains site-specific recombinase genes). The SCC mec el-
ements have been classified into eight types (I–VIII)
based on the structure and combination of mec and ccr
gene complexes present. These elements also differ in
what other antimicrobial resistance genes are carried
on them. Types I, IV, V, VI, and VII generally do not
carry other resistance genes. Types II, III, and VIII may
contain one or more other resistance genes, such as
ermA (erythromycin), aadD (tobramycin), and tetK
(tetracycline). These types are also used to help
distinguish CA-MRSA and HA-MRSA strains. Most
HA-MRSA strains carry SCC mec types I, II, III, VI,
and VIII; while most CA-MRSA strains carry types IV,
with some carrying types V and VII [51]. If MRSA is
suspected (both HA and CA-MRSA), glycopeptides and
other antimicrobial options are available agents. Also,
new options such as dalbavancin and tedizolid also can
be administered.
What oral antibiotics can be used for the
management of MRSA skin and soft-tissue
infections (SSTIs)? What intravenous antibiotics
can be used for the management of MRSA skin
and soft-tissue infections?
For oral antibiotic coverage of MRSA in patients with
SSTI, we suggest the following agents: linezolid
(recommendation 1A), trimethoprim-sulfamethoxazole
(TMP-SMX) (recommendation 1B), a tetracycline
(doxycycline or minocycline) (recommendation 1B), or
tedizolid (Recommendation 1A).
For intravenous (IV) antibiotic coverage of MRSA in
patients with SSTI, we suggest the following agents:
daptomycin (10mg/kg/dose IV once daily) (recommen-
dation 1A), IV linezolid (recommendation 1A), IV
ceftaroline (recommendation 1A), IV dalbavancin (rec-
ommendation 1A), IV vancomycin (recommendation
1A), IV tigecycline (recommendation 1A), or IV tedizo-
lid (recommendation 1A).
Seven to 14 days of therapy is recommended but
should be individualized on the basis of the patient’s
clinical response (recommendation 1A). IV to oral
switch should occur when criteria of clinical stability
have been reached (recommendation 1C).
For CA-MRSA, recommended oral agents are clinda-
mycin, although clindamycin resistance is now very
common [52], tetracyclines, TMP-SMX, linezolid, tedi-
zolid, and occasionally, fluoroquinolones. Several obser-
vational studies and one small randomized trial [53, 54]
suggest that TMP-SMX, doxycycline, and minocycline
are effective for such infections. If coverage for both
streptococci and MRSA is desired for oral therapy, op-
tions include clindamycin alone, or the combination of
either TMP-SMX or doxycycline with a beta-lactam
(e.g., penicillin, cephalexin, or amoxicillin).
Glycopeptides have been for many years the microbio-
logical agents of choice used in complicated Gram-positive
infections. Fortunately, staphylococcal resistance to glyco-
peptides remains rare, although rising minimal inhibitory
concentrations (MICs) of glycopeptides may affect the effi-
cacy of these antibiotics [55, 56].
Increased resistance to glycopeptides has encouraged the
development of new agents active against Gram-posi-
tive bacteria, particularly for severe soft-tissue
infections where aggressive antimicrobial management
is always recommended, such as linezolid and
daptomycin. Linezolid has been considered an agent
of choice in complicated skin and soft-tissue infec-
tions (cSSTIs). It has the advantages of early intraven-
ous-to-oral switch with the oral preparation having
very high bioavailability and excellent tissue penetra-
tion [57].
In 2010, an open-label study compared oral or intra-
venous linezolid with intravenous vancomycin for
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treatment of cSSTIs caused by MRSA [58]. Patients re-
ceiving linezolid had a significantly shorter length of stay
and duration of intravenous therapy than those receiving
vancomycin. Both agents were well tolerated. Adverse
events were similar to each drug’s established safety pro-
file [58].
Recently, a Cochrane meta-analysis included all random-
ized controlled trials comparing linezolid with vancomycin
in the treatment of SSTIs [59]. Linezolid was associated
with a significantly better clinical (risk ratio [RR] = 1.09,
95% CI, 1.03–1.16) and microbiological cure rate in adults
(RR = 1.08; 95% CI, 1.01–1.16). For infections caused by
MRSA, linezolid was significantly more effective than
vancomycin in clinical (RR = 1.09; 95% CI, 1.03–1.17) and
microbiological cure rates (RR = 1.17; 95% CI, 1.04–1.32).
The daily cost of outpatient therapy was less with oral
linezolid than with intravenous vancomycin. Although
inpatient treatment with linezolid cost more than in-
patient treatment with vancomycin per day, the median
length of hospital stay was 3 days shorter with linezolid.
Daptomycin has proven efficacy in patients with
Gram-positive complicated ©SSTIs, including those caused
by S. aureus resistant to methicillin [60]. Daptomycin has
been shown to achieve very good concentrations in the skin
and soft tissues. In 2010, a meta-analysis compared effective-
ness and toxicity of daptomycin with that of other antimicro-
bials for the treatment of SSTIs. Four studies were included
in the analysis (three were randomized RCTs). Vancomycin
and semisynthetic penicillins were used in the comparator
arm. Three studies reported on patients with cSSTIs. Dapto-
mycin tissue penetration supports its use in the treatment of
cSSTIs, and it has been shown to be non-inferior to vanco-
mycin and semisynthetic penicillins [61].
Ceftaroline is an oxyimino advanced-generation broad-
spectrum cephalosporin which has in vitro activity against
S. aureus and MRSA, both of which are associated with
cSSTIs. Ceftaroline fosamil has been found to be effective
in the treatment of cSSTI when compared with vanco-
mycin plus aztreonam for the treatment of cSSTI [62–64].
Ceftaroline fosamil was also well tolerated and had a
safety profile concordant with other antibiotics in the
cephalosporin class.
More recently, new drugs have been approved for
ABSSSI and have an important activity against MRSA,
especially dalbavancin and tedizolid. Tedizolid, a novel
oxazolidinone with Gram-positive activity including
MRSA, is promising because it can be administered
daily in oral or intravenous forms [65, 66], and dalba-
vancin, a second-generation lipoglycopeptide that
covers MRSA, can be administered as infrequently as
once weekly [67, 68].
Antibiotics recommended for MRSA infections are
listed below.
Oral options:
 Minocycline100 mg q12h
 Trimethoprim and sulfamethoxazole 160/800 mg
q12h
 Doxycycline 100 mg q12h
 Clindamycin 300–600 mg q8h (high resistance rate)
 Linezolid 600 mg q12h
 Tedizolid 200 mg q24 h
Intravenous options:
 Vancomycin 15 mg/kg IV q12h
 Teicoplanin LD 12 mg/kg IV q12h for 3 doses, then
6 mg/kg q12h
 Tigecycline 100 mg IV as a single dose, then 50 mg
IV q12h
 Linezolid 600 mg q12h
 Daptomycin 4–6 mg/kg q24h
 Ceftaroline 600 mg q12h
 Dalbavancin 1000 mg once followed by 500 mg after
1 week or 1500 mg one dose
 Tedizolid 200 mg q24h
The decision to use intravenous or oral agents has
been debated. Currently, oral therapy is recommended
for mild infections and intravenous therapy for severe
infections. Moderate infections may be treated via the
oral route, or with one to two intravenous doses and
then transitioning to oral therapy. For patients with
severe infections who are able to tolerate oral therapy
and in whom clinical improvement has been docu-
mented, the goal should be to transition to the oral
route as soon as possible. There is evidence to sug-
gest that this approach positively impacts length of
stay as well [69].
What are necrotizing infections?
Necrotizing soft-tissue infections (NSTIs) are life-threat-
ening, invasive, soft-tissue infections with a necrotizing
component involving any or all layers of the soft-tissue
compartment, from the superficial dermis and subcuta-
neous tissue to the deeper fascia and muscle. The latter
is most commonly called “necrotizing fasciitis” [70].
The necrotizing or non-necrotizing character of the
infection should be always specified when classifying
patients with soft-tissue infections (recommendation
1C).
Delay in diagnosis and delay in treatment of these in-
fections increase the risk of mortality. Because of its ag-
gressive character, NSTIs should always be differentiated
from non-necrotizing infection. Several definitions were
published over the last few years, and all these defini-
tions can be confusing. NSTIs are defined by the pres-
ence of a spreading infection in any of the layers of the
soft tissues (skin, subcutaneous tissue, superficial fascia,
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deep fascia, or muscles) which is associated with the
presence of necrosis of the layer(s) involved and hence
requires surgical debridement. All NSTIs fulfill this def-
inition and have common features in their clinical pres-
entation and diagnosis, and most importantly, all of
these infections by definition require surgical debride-
ment. Therefore, labeling them with different terms does
not serve a useful purpose and may in fact complicate
management by delaying diagnosis and/or delaying sur-
gical debridement [7, 8, 10].
How can necrotizing infections be classified?
Patients with NSTIs should be classified into the
following:
 High risk of poor outcome.
 Mild/moderate risk of poor outcome.
Scores used for severity assessment of patients with
necrotizing infections may be useful in the emer-
gency room or outside the intensive care unit (ICU)
and may identify patients early, who require surgical
treatment and perioperative intensive care manage-
ment (recommendation 1C).
Several classifications of NSTIs have been proposed;
however, none are universally accepted. Necrotizing in-
fections have been described according to their ana-
tomical locations (i.e., Fournier gangrene) and the
depth of infections: dermal and subcutaneous compo-
nents (necrotizing cellulitis), fascial component (necro-
tizing fasciitis), and muscular components (necrotizing
myositis). NSTIs may also be classified into three types
defined by the bacterial pathogens initiating the infec-
tion and their typical clinical characteristics: type 1—
polymicrobial, type 2—mono-microbial pathogenic
β-hemolytic streptococci or CA-MRSA, and type 3—
mono-microbial secondary to a variety of pathogenic
bacilli. However, resolution of these nomenclature is-
sues requires a consensus among international infec-
tious disease physicians, surgeons, and intensivists, and
probably, these various methods of classification are
not clinically useful. Although many specific variations
of NSTIs have been described, the initial approach to
diagnosis, antimicrobial treatment, and surgical inter-
vention is similar for all forms and identifying those in-
fections needing immediate aggressive management is
more important than determining the specific variant.
Delay in diagnosis and/or treatment of NSTIs corre-
lates with a poor outcome, leading to multiple organ
failure. Early prognostic evaluation of NSTIs is crucial to
assess the severity and decide the aggressiveness of treat-
ment. Necrotizing infections remain an important
source of patient morbidity and are frequently associated
with poor clinical prognosis. Any process of improving
quality of care for necrotizing infections globally should
focus on simple diagnostic criteria based on physical
examination findings and recognition of patients need-
ing timely critical care.
A classification of patients based on a severity as-
sessment which could identify cases requiring surgical
and critical care may be an important tool both in
ICU and outside of the ICU. The Laboratory Risk In-
dicator for Necrotizing Fasciitis (LRINEC) score first
published in 2004 [71] is based on routinely per-
formed parameters and offers a method to identify
NSTIs at early stage. With a score of 8 or higher,
there is a 75% risk of a NSTI.
A systematic review of English-language literature
from 2004 to 2014 to identify articles reporting use
of LRINEC score and the incidence of necrotizing fas-
ciitis was recently published [72]. After application of
inclusion criteria, 16 studies with 846 patients were
included. The authors concluded that the LRINEC
score is a useful clinical determinant in the diagnosis
and surgical treatment of patients with necrotizing
fasciitis, with a statistically positive correlation
between LRINEC score and a true diagnosis of necro-
tizing fasciitis. A second meta-analysis including
English-language studies reporting the diagnostic ac-
curacy of LRINEC score was recently published [73].
Twenty-three studies (n = 5982) were included. LRI-
NEC ≥ 6 had sensitivity of 68.2% and specificity of
84.8%, while LRINEC ≥ 8 had sensitivity of 40.8% and
specificity of 94.9%. The authors concluded that due
to poor sensitivity, LRINEC should not be used to
rule-out NSTIs.
In the setting of such aggressive infections, a feasible,
low-cost method of rapidly identifying patients requiring
critical care is crucial [74]. Early warning system scores
utilize physiological, easy-to-measure parameters, asses-
sing physiological parameters such as systolic blood
pressure, pulse rate, respiratory rate, temperature, oxy-
gen saturation, and level of consciousness. They are sim-
ple, non-invasive, and easy-to-repeat measurement at
the bedside.
The Sepsis-3 definitions [75] suggest that patients with
at least two of these three clinical variables may be
prone for the poor outcome typical of sepsis: (1) low
blood pressure (systolic blood pressure ≤ 100 mmHg), (2)
high respiratory rate (≥ 22 breaths per minute), or (3) al-
tered mentation (Glasgow coma scale < 15) (quick SOFA
[qSOFA]). It is supposed to be useful in out-of-hospital,
emergency surgery, or general hospital ward settings,
and in patients with positive qSOFA, organ dysfunction
should be investigated. The qSOFA score should not be
regarded as a diagnostic criterion for defining sepsis. Ra-
ther, it should be regarded as a warning for patients with
suspected infection who are likely to have poor
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outcomes. In the setting of patients with necrotizing in-
fections, it may be useful as a warning for patient’s se-
verity assessment.
Is a multidisciplinary approach to necrotizing
infections mandatory?
A multidisciplinary team is mandatory for the man-
agement of NSTIs. Depending on the time line, vari-
ous specialties are involved. Specific attention should
be given to the long-term management of these pa-
tients (recommendation 1C).
NSTIs rank among one of the more difficult disease
processes encountered by physicians. The most critical
factors for reducing mortality in NSTIs are early recogni-
tion and urgent operative debridement. Initial treatment
of patients with necrotizing infections should always re-
quire coordination between the surgeons, intensivists, and
infectious disease specialist. Treatment consists of radical
debridement associated with broad-spectrum antimicro-
bial therapy and hemodynamic support.
Moreover, the magnitude of necrotic tissues that need
to be radically debrided, although required to save the
patient’s life, often create unique and difficult challenges
in terms of wound care, preservation of function, recon-
struction, and cosmesis. These problems require time
and a multidisciplinary approach. After an extended
hospitalization, multiple dressing changes, and surgical
procedures, the survivor of NSTI faces months of con-
tinued physical therapy to regain functional independ-
ence, whenever possible. Rehabilitation is an essential
and integral component of recovery [76].
What is the pathophysiology of necrotizing
infections
Due to the rapid progression of the inflammatory
process, early treatment of necrotizing infection is al-
ways recommended (recommendation 1C).
There are two main ways by which bacteria can invade
soft tissues. The most common way is through a break in
the skin barrier. In case of contamination by spores of C.
perfringens, the anaerobic environment (caused by impair-
ment of the blood supply resulting in tissue hypoxia) is
necessary for maturation and proliferation of Clostridium
strains [77]. The second way is hematogenous spread of
bacteria to the tissue; however, it is a rare condition. Local
and systemic manifestations are related to specific patho-
physiologic mechanisms depending upon the toxins and
enzymes of involved bacteria.
Bacteria proliferate and release toxins, which cause local
tissue damage and impair inflammatory responses. Some
toxins produce thrombosis of larger venules and arteri-
oles, with subsequent ischemic necrosis of all tissue layers,
from the dermis to the deep muscles [77]. Systemic
manifestations are also related to toxin-mediated
pathophysiologic mechanisms and include fever,
hypotension, tachycardia, altered mental status, and signs
of organ dysfunction. In principle, these mechanisms may
involve both host and pathogen factors. Host-related fac-
tors are determined by human genes that control release
of cytokines and encode pro-inflammatory cytokines elicit-
ing subsequent counter-regulatory mechanisms. Microbial
virulence factors include Gram-positive and Gram-negative
bacterial products. These toxins are absorbed in the blood-
stream. Bacterial superantigens (pyrogenic exotoxins) dir-
ectly stimulate and non-specifically activate high numbers
of T cells and macrophages to produce pro-inflammatory
mediators such as TNF-α, IL-1, and IL-6. The massive re-
lease of these cytokines produces an uncontrolled systemic
inflammatory response that can lead to multisystem organ
dysfunction and shock [77].
How can necrotizing infections be diagnosed?
Clinical signs of NSTI include pain out of propor-
tion, edema extending beyond the erythema, and
fever. A rapidly progressive soft-tissue infection
should always be suspected as a necrotizing infec-
tion (recommendation 1C).
The initial differential diagnosis between a cellulitis
and a necrotizing infection that requires prompt opera-
tive intervention may be difficult. Most cases of NSTI
are initially diagnosed and begin as cellulitis. However,
since time to operative debridement is an important de-
terminant of outcome in necrotizing infections, timely
diagnosis is essential.
Patients with NSTI usually present with severe pain
which is out of proportion to the physical findings [78–82].
Typical local signs are as follows:
 Edema
 Erythema
 Severe and crescendo pain out of proportion
 Skin bullae or necrosis (at later stage)
 Swelling or tenderness
 Crepitus
Systemic signs are as follows:
 Fever
 Tachycardia
 Hypotension
 Shock
Laboratory tests are not highly sensitive or specific for
NSTIs. A rapidly progressive soft-tissue infection should
be treated as a necrotizing infection, from the beginning.
The clinical picture may worsen very quickly, sometimes
during a few hours.
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In order to predict the presence of NSTI, the Laboratory
Risk Indicator for Necrotizing infection (LRINEC) score
was proposed [71]. LRINEC score assigns points for abnor-
malities in six independent variables: serum C-reactive pro-
tein level (> 150mg/L), white blood cell (WBC) count (>
15,000/μL), hemoglobin level (< 13.5 g/dL), serum sodium
level (< 135mmol/L), serum creatinine level (> 1.6mg/dL
[142mmol/l]), and serum glucose level (> 180mg/dL [10
mmol/l]). With a score of 8 or higher, there is a 75% risk of
a NSTI.
Subsequent evaluation of the LRINEC score has demon-
strated conflicting results. Several studies have assessed
the utility of LRINEC for the early diagnosis of necrotizing
infections [72, 83–88].
Recent evidence has demonstrated that it lacks the
sensitivity to be a useful adjunct for the diagnosis of nec-
rotizing infections [73].
The diagnosis of necrotizing infection is primarily a
clinical diagnosis. However, radiologic imaging may be
able to provide useful information when the diagnosis
is uncertain. A plain X-ray should not be used to
rule-out necrotizing infection (recommendation 1B).
In unstable patients, ultrasound may be useful to
differentiate simple cellulitis from necrotizing fasci-
itis (recommendation 2C).
Imaging studies should not delay surgical consult-
ation and intervention (recommendation 1A).
Frequently, plain radiographs are normal or with in-
creased soft-tissue thickness and opacity, unless the in-
fection and necrosis are advanced. The characteristic
finding is gas in the soft tissues, but subcutaneous gas is
present only in few cases of necrotizing infection and is
not present in pure aerobic infections such as those
caused by S. pyogenes.
Additionally, subcutaneous gas may not be present in
earlier stages of the disease process and only become
manifest as the patient’s condition deteriorates [89, 90].
Computed tomography (CT) has a higher sensitivity
than plain radiography in identifying early NSTIs. Find-
ings consistent with necrotizing infections are fat strand-
ing, fluid and gas collections that dissect along fascial
planes, and gas in the involved soft tissues. Additionally,
fascial thickening and non-enhancing fascia on contrast
CT suggests fascial necrosis [91].
In 2010, a case series study [92] analyzing the use of CT
scanning for the diagnosis of NSTIs was published. Of 67
patients with study inclusion criteria, 58 underwent surgi-
cal exploration, and NSTIs was confirmed in 25 (43%).
The remaining 42 patients had either non-necrotizing
infections during surgical exploration (n = 33) or were
treated non-operatively with successful resolution of the
symptoms (n = 9). The sensitivity of CT to identify NSTI
was 100%, specificity was 81%, positive predictive value
was 76%, and negative predictive value was 100%.
Magnetic resonance imaging (MRI) has been the im-
aging modality of choice for necrotizing fasciitis. Patients
with necrotizing fasciitis usually have a significantly
greater frequency of the following MRI findings: thick
(≥ 3 mm) abnormal signal intensity on fat-suppressed
T2-weighted images, low signal intensity in the deep
fascia on fat-suppressed T2-weighted images, a focal or
diffuse non-enhancing portion in the area of abnormal
signal intensity in the deep fascia, extensive involvement
of the deep fascia, and involvement of three or more
compartments in one extremity [93]. However, MRI may
be difficult to perform under emergency conditions and
is not recommended as the first-choice imaging
technique.
Ultrasound has the advantage of being rapidly per-
formed at bedside and may be helpful in differentiating
simple cellulitis from necrotizing fasciitis. In a prospect-
ive observational study of 62 patients with clinically sus-
pected necrotizing fasciitis, ultrasound had a sensitivity
of 88.2%, specificity of 93.3%, positive predictive value of
95.4%, negative predictive value of 95.4%, and diagnostic
accuracy of 91.9%. The authors considered the findings
of diffuse subcutaneous thickening accompanied by fluid
accumulation of > 4 mm in depth along the deep fascial
layer predictive of necrotizing fasciitis [94].
Rapid performance of frozen-section soft-tissue biopsy,
early in the evolution of a suspect lesion, may provide a
definitive and life-saving diagnosis. Triple diagnostics
which include an incisional biopsy over the most sus-
pected area, a fresh frozen section and Gram staining
might be an important adjunct in early stages of sus-
pected necrotizing infections (recommendation 1C).
Early frozen-section diagnosis should be limited to
those cases in which the clinical or radiographic findings
are not diagnostic (recommendation 1C).
Fascial biopsy with frozen section has been suggested
as a means to achieve earlier diagnosis of NSTIs [95,
96]. However, frozen-section biopsy is not very practical
and requires availability and experience of the patholo-
gists, and the time taken to carry out and analyze the
sample could be used for debridement [97]. The Finger
test is another adjunct method described for diagnosing
NSTIs. It is performed under local anesthesia. A 2-cm
incision is made down to the deep fascia. Minimal tissue
resistance to finger dissection (positive Finger test), the
absence of bleeding, presence of necrotic tissue, and/or
murky and grayish (“dishwater”) fluid following incision,
all suggest the diagnosis of NSTI [98].
What is the best timing of source control?
Provide (surgical) source control in patients with
NSSTI as soon as possible, but at least within the
first 12 h after admission, in patients with a high sus-
picion for necrotizing infection. Early source control,
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antimicrobial therapy, and (organ) supportive mea-
sures are the cornerstone of treatment in patients
with sepsis or septic shock caused by NSSTI (recom-
mendation 1B).
Source control for SSTIs includes drainage of infected
fluids, debridement of infected soft tissues, and removal
of infected devices or foreign bodies. It should also in-
clude definitive measures to correct any anatomic de-
rangement resulting in ongoing microbial contamination
and restoring optimal function. Early surgical debride-
ment with complete removal of necrotic tissue is essen-
tial to decrease mortality and other complications in
patients with NSTIs. It is the most important determin-
ant of outcome in necrotizing infections. This was well
described in a study by Bilton et al. in which patients
with NSTIs, who had adequate surgical debridement
(early and complete), were compared to those with ei-
ther delayed or incomplete debridements. The mortality
in the latter group was 38% compared to 4.2% in the
group receiving early adequate surgical treatment [99].
Delay in source control in patients with NSTIs has
been repeatedly associated with a greater mortality. A
retrospective study including 47 patients with the diag-
nosis of NSTI admitted to a large academic hospital
from December 2004 to December 2010 was published
in 2011 [100]. Overall mortality was 17.0%. The average
number of surgical debridements in patients with surgi-
cal treatment delayed > 12 h from the time of emergency
department admission was significantly higher than
those who had an operation within 12 h after admission
(7.4 ± 2.5 versus 2.3 ± 1.2; p < 0.001). Delayed surgical de-
bridement was associated with significantly higher mor-
tality, higher incidence of septic shock and renal failure,
and more surgical debridements than patients with early
surgical debridements. After adjusting for possible con-
founding factors, the average number of surgical de-
bridements and the presence of septic shock and acute
renal failure were still significantly higher in patients in
whom surgery was delayed > 12 h.
A retrospective study including 106 patients with nec-
rotizing infections conducted in a medical ICU was pub-
lished in 2009 [101]. Overall hospital mortality was
40.6%. In multivariate analysis, underlying cardiovascular
disease, SAPS II, abdomino-perineal compared to limb
localization, time from the first signs to diagnosis < 72 h,
and time from diagnosis to surgical treatment > 14 h in
patients with septic shock were independently associated
with hospital mortality.
A retrospective study of 121 patients (mean age, 65.2
± 11.6 years) with Vibrio vulnificus-related necrotizing
infection who underwent surgical intervention between
July 1998 and June 2011 was published in 2011 [102].
The patients were divided into three groups according
to the time between admission and surgical treatment as
follows: surgical treatment less than 12 h after admis-
sion, 12 to 24 h after admission, and more than 24 h
after admission. Patients who underwent surgery less
than 12 h after admission had a significantly lower mor-
tality compared with those who had surgery either 12 to
24 h after admission (adjusted hazard ratio [HR], 0.064;
95% CI, 1.6 × 10−7 to 0.25; p = 0.037) or more than 24 h
after admission (adjusted HR, 0.0043; 95% CI, 2.1 × 10−5
to 0.0085; p = 0.002). There was no difference in mortal-
ity risk between patients who underwent surgery 12 to
24 h after admission and those who had surgery more
than 24 h after admission (p = 0.8).
We suggest to remove only devitalized/infarcted skin
and spare normally perfused skin. In case where skin
viability is questionable, skin preservation and reassess-
ment at the second operation is indicated (recommenda-
tion 1C).
Once the decision to take the patient for an operation
has been made, the initial incision is done in the com-
promised area and the wound is explored for macro-
scopic findings of NSTIs. Incision should take place
along the involved muscular lodges. Removal of all
non-viable tissue should be accomplished including
muscle, fascial layers, subcutaneous tissue, and skin if
they are compromised, and one should extend the inci-
sion until healthy viable tissue is seen. Removal of previ-
ously viable skin or muscle should usually not be done
at the initial operation, attempting skin sparing via mul-
tiple incisions (to preserve perforators), while accounting
for underlying bone, nerve, and vascular structures. Skin
perfusion and viability can easily be assessed at
re-exploration, and removal at that time is easy, if indi-
cated. The wound should always be left open. Amputa-
tion of a limb does not add to the acute debridement
and should be reserved for late and extreme
presentations.
What is the best timing of re-exploration?
Consider to plan the first re-exploration within 12–
24 h and to repeat re-exploration(s) until the patient
is free of necrosis (recommendation 1C).
There is a lack of literature examining outcomes in
necrotizing infections when surgical re-debridements are
performed in early versus delayed intervals. Scheduled
re-explorations should be done at least every 12–24 h
after the initial operation or sooner if clinical local or
systemic signs of worsening infection become evident, as
well as with worsening laboratory parameters (particu-
larly WBC count). Re-explorations should be repeated
until the time when very little or no debridement is
required.
A prospective observational study by Okoye et al.
[103] showed that delayed re-debridement after initial
source control in necrotizing infections results in worse
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survival and an increased incidence of acute kidney in-
jury. The authors concluded that further studies to iden-
tify the optimal time interval for re-debridement are
warranted.
What is the role of hyperbaric oxygen therapy
(HBO) for source control in necrotizing infections?
Consider adjuvant hyperbaric oxygen therapy in
patients with NSTI after prompt debridement (recom-
mendation 2B).
Despite significant advancements in critical care man-
agement as well as improved knowledge regarding NSTIs,
mortality remains relatively high. Adjunctive and less con-
ventional treatment options have been explored in an
effort to improve outcomes in this group of patients.
Hyperbaric oxygen (HBO) is one of these modalities. It is
a medical treatment that uses delivery of 100% oxygen at a
pressure of 2–3 absolute atmospheres. Its use is motivated
by the fact that oxygen delivery at these parameters
achieves a much higher concentration of dissolved oxygen
in blood which results in higher tissue oxygen tensions. At
this higher tissue tension, beneficial effects may be seen
including improved leukocyte function, inhibition of
anaerobic growth, inhibition of toxin production, and
enhancement of antibiotic activity.
The role of HBO as an adjunctive treatment has been
debated, and no prospective randomized clinical trials
have been published. In order to determine the effect of
hyperbaric oxygen HBO therapy on mortality, compli-
cation rate, discharge status/location, hospital length of
stay, and inflation-adjusted hospitalization cost in pa-
tients with NSTIs, a retrospective study of 45,913 pa-
tients in the Nationwide Inpatient Sample from 1988 to
2009 was published in 2012 [104]. This retrospective
analysis of HBO therapy in NSTI showed that despite
the higher hospitalization cost and longer length of
stay, the statistically significant reduction in mortality
supports the use of HBO therapy in NSTI (RR = 0.47;
95% CI, 0.30–0.74). In 2013, a review about HBO ther-
apy for treating acute surgical and traumatic wounds
was published [105]. The authors concluded that there
is a lack of high-quality, valid research evidence regard-
ing the effects of HBO therapy on wound healing.
HBO could be useful, if available, but it should not
interfere with the standard treatment. Furthermore, the
patient should not be transferred to carry out HBO ther-
apy, thereby delaying standard care.
What is the role of intravenous immunoglobulin
(IVIG) therapy for source control in necrotizing
infections?
Consider intravenous immunoglobulin (IVIG) ther-
apy in patients with necrotizing infections caused by
GAS (recommendation 2B).
Intravenous immunoglobulin therapy has been postu-
lated to improve outcomes in a selected population of
patients with NSTIs. Most of the reported studies evalu-
ated its use for invasive GAS infections including
GAS-related NSTIs with streptococcal toxic shock syn-
drome (STSS).
The efficacy and safety of high-dose IVIG as ad-
junctive therapy in STSS were evaluated in a multicen-
ter, randomized, double-blind, placebo-controlled trial
[106]. The trial was prematurely terminated because
of slow patient recruitment, and results were obtained
from 21 enrolled patients (10 IVIG recipients and 11
placebo recipients). The primary end point was mor-
tality at 28 days, and a 3.6-fold non-significant higher
mortality rate was found in the placebo group. A sig-
nificant decrease in the sepsis-related organ failure as-
sessment score at days 2 (p = 0.02) and 3 (p = 0.04)
was noted in the IVIG group. Furthermore, a signifi-
cant increase in plasma neutralizing activity against
superantigens expressed by autologous isolates was
noted in the IVIG group after treatment (p = 0.03). Al-
though statistical significance was not reached in the
primary end point, the trial provides some supportive
evidence for IVIG as an efficacious adjunctive therapy
in STSS. IVIG therapy role in improving survival in
STSS was also demonstrated in other prospective
studies [107, 108].
In 2017, a retrospective study of adult patients with
necrotizing fasciitis and vasopressor-dependent shock
undergoing surgical debridement from 2010 to 2014 in
130 US hospitals was published [109]. Of 4127 cases of
debrided necrotizing infection with shock at 121 centers,
only 164 patients (4%) at 61 centers received IVIG. IVIG
subjects were younger with lower comorbidity indices,
but higher illness severity. Clindamycin and vasopressor
intensity were higher among IVIG cases, as was coding
for TSS and GAS. In-hospital mortality did not differ be-
tween matched IVIG and non-IVIG groups (crude mor-
tality, 27.3 versus 23.6%; adjusted HR, 1.00 [95% CI,
0.55–1.83]; p = 0.99). Early IVIG (≤ 2 days) did not alter
this effect (p = 0.99). Among patients coded for TSS,
GAS, and/or S. aureus, IVIG use was still unusual (6.8%)
and lacked benefit (p = 0.63). Median LOS was similar
between IVIG and non-IVIG groups (26 [13–49] versus
26 [11–43]; p = 0.84).
Recently, a Cochrane review on intervention for NSTIs
was published [110]. One trial of 100 randomized partic-
ipants assessed IVIG as an adjuvant drug, given at a dose
of 25 g/day, compared with placebo, given for three con-
secutive days. No clear difference between IVIG and pla-
cebo in terms of mortality within 30 days (RR = 1.17;
95% CI, 0.42–3.23), nor serious adverse events experi-
enced in the ICU (RR = 0.73; 95% CI, 0.32–1.65) were
observed.
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What are the resuscitation principles in patients
with necrotizing infection?
Supportive treatment in managing necrotizing infec-
tions must be early and aggressive to halt progression
of the inflammatory process (recommendation 1A).
Early detection of sepsis and prompt aggressive treat-
ment of the underlying organ dysfunction is an essential
component for improving outcomes of critical ill pa-
tients [111]. Necrotizing infections may present with a
fulminant course and may be associated with great mor-
bidity and high case-fatality rates, especially when they
occur in conjunction with TSS.
Early blood cultures, empirical antibiotic treatment,
and intensive care for hemodynamic and metabolic sup-
port should be performed as soon as possible. Moreover,
patients may lose fluids, proteins, and electrolytes
through a large surgical wound [112]. In addition,
hypotension is caused by vasodilation induced by the
systemic inflammatory response syndrome to infection
[113]. Fluid resuscitation and analgesia are the mainstays
of support for patients with advanced sepsis usually
combined with vasoactive amines associated with mech-
anical ventilation and other organ function supports, if
needed. No ideal fluid exists: resuscitation therapy must
be prompt and immediate as in any type of shock.
What are the new agents to treat necrotizing
infections
AB103 (Reltecimod) is a new agent for modulation of
inflammation after necrotizing infections. Further
study is warranted to establish efficacy (no
recommendation).
AB103 (Reltecimod) is a safe and promising new agent
for modulation of inflammation after a necrotizing infec-
tions. However, further studies are warranted to establish
efficacy.
AB103 (originally p2TA) is a novel synthetic CD28 mi-
metic octapeptide that selectively inhibits the direct
binding of superantigen exotoxins to the CD28 costimu-
latory receptor on T-helper 1 lymphocytes [114].
Preclinical studies demonstrated that AB103 and re-
lated superantigen mimetic peptides are associated with
improved survival in animal models of toxic shock and
sepsis. The hypothesis is that AB103 could be adminis-
tered safely in patients presenting with NSTI and would
modulate the immune response to reduce the develop-
ment or progression of organ failure.
To establish the safety of AB103 in patients with NSTI
and evaluate the potential effects on clinically meaning-
ful parameters related to the disease [115], a prospective,
randomized, placebo-controlled, double-blinded study
was performed in six academic medical centers in the
USA. Participants included adults with NSTI. Of 345 pa-
tients screened, 43 were enrolled for the intent-to-treat
analysis, and 40 met criteria for the modified
intent-to-treat analysis; 15 patients each were included
in the high-dose and low-dose treatment arms, and 10
in the placebo arm. Baseline characteristics were com-
parable in the treatment groups. The Sequential Organ
Failure Assessment score improved from baseline in
both treatment groups compared with the placebo
group at 14 days (change from baseline score, − 2.8 in
the high-dose, − 2 in the low-dose, and + 1.3 in the pla-
cebo groups; p = 0.04). AB103-treated patients had a
similar number of debridements (mean [SD], 2.2[1.1]
for the high-dose, 2.3[1.2] for the low-dose, and 2.8
[2.1] for the placebo groups; p = 0.56). There were no
statistically significant differences in ICU-free and
ventilator-free days or in plasma and tissue cytokine
levels. No drug-related adverse events were detected. A
phase 3 trial, also known as the ACCUTE trial (Relteci-
mod Clinical Composite Endpoint Study in Necrotizing
Soft Tissue Infections), has been designed as a single
pivotal study to assess the efficacy and safety of Relteci-
mod versus placebo in patients with necrotizing
infections.
What antibiotics are recommended for empiric
treatment of clinically suspected necrotizing
infections?
Antibiotic treatment of necrotizing infections should
be prompt and aggressive (recommendation 1B).
The initial empirical antibiotic regimen should com-
prise broad-spectrum drugs including anti-MRSA and
anti-Gram-negative coverage (recommendation 1C).
Vancomycin treatment should be avoided in patients
with renal impairment and when MRSA isolate shows
a MIC for vancomycin ≥ 1.5mg/mL (recommendation
1B).
Daptomycin or linezolid are drugs of choice for
empirical anti-MRSA coverage. Alternatively, ceftaro-
line, telavancin, tedizolid, and dalbavacin can be used
(recommendation 2C).
The choice of anti-Gram-negative treatment should
be based on local prevalence of ESBL-producing
Enterobacateriaceae and multidrug-resistant organ-
isms (MDROs) non-fermenters (recommendation
1B).
De-escalation of antibiotic therapy should be based on
clinical improvement, cultured pathogens, and results of
rapid diagnostic tests where available (recommendation
1C).
Microbiologically, NSTIs have been classified as either
type 1 (polymicrobial) or type 2 (mono-microbial) or
type 3 (gas gangrene). Occasionally in immunocom-
promised patients, NSTIs may be also caused by mycotic
species.
Sartelli et al. World Journal of Emergency Surgery           (2018) 13:58 Page 16 of 24
NSTIs type I is a polymicrobial infection involving aer-
obic and anaerobic organisms. It is usually seen in the
elderly or in those with underlying illnesses [77]. Type I
infection is often associated with gas in the tissue and
thus is difficult to distinguish from gas gangrene.
Non-clostridial anaerobic cellulitis and synergistic necro-
tizing cellulitis are type I variants. Both occur in patients
with diabetes and typically involve the feet, with rapid
extension into the leg.
NSTI type II is a mono-microbial infection. Among
Gram-positive organisms, GAS remains the most common
pathogen, followed by MRSA. Unlike type I infections, type
II infections may occur in any age group and in persons
without any underlying illness. Other pathogens include
Aeromonas hydrophila and V. vulnificus. Mono-microbial
necrotizing fasciitis due to Gram-negative pathogens (bacter-
oides and E. coli) have also been reported, though these in-
fections are typically seen in immunocompromised, diabetic,
obese, and postoperative patients [77].
Gas gangrene (clostridial myonecrosis), or type III
NSTI, is an acute infection by clostridium or bacillus of
healthy living tissue that occurs spontaneously or as a
result of traumatic injury. Recurrent gas gangrene, oc-
curring several decades after the primary infection, has
also been described.
The use of antimicrobial therapy is an adjuvant treat-
ment and must be combined with early surgical debride-
ment. Once the diagnosis is made and blood cultures
have been drawn, broad-spectrum coverage should be
urgently commenced. Initial antibiotic therapy for necro-
tizing infections is empirical in nature because microbio-
logical data (culture and susceptibility results) may
require > 24 h before they are available for a more de-
tailed analysis.
Since it is impossible to exclude with certainty a polymi-
crobial necrotizing infection, an aggressive broad-spectrum
empiric antimicrobial therapy should initially be selected to
cover Gram-positive, Gram-negative, and anaerobic organ-
isms until culture-specific results and sensitivities are avail-
able. An acceptable empiric antibiotic regimen should
always include antibiotics, which cover MRSA with the
additional benefit of inhibiting invasive GAS virulence pro-
teins. For the treatment of MRSA, we refer to the previous
paragraphs.
For the treatment of Gram-negative bacteria, the use of
piperacillin-tazobactam in the setting without high local
prevalence of ESBL-producing Enterobacateriaceae opti-
mizing pharmacokinetic/pharmacodynamic parameters is
appropriate. Carbapenems, administered in adequate
dosage, including meropenem, imipenem-cilastatin, or
doripenem may be used in the settings with high local
prevalence of ESBL-producing Enterobacateriaceae.
Culture-specific results and sensitivities can direct both
broadening of antimicrobial regimen if it is too narrow
and a de-escalation if it is too broad particularly in critic-
ally ill patients where de-escalation strategy is one of the
cornerstones of antimicrobial stewardship programs [116].
The choice of anti-Gram-negative treatment should be
based on local prevalence of ESBL-producing Enterobaca-
teriaceae and MDRO non-fermenters.
Should an antitoxin active drug (clindamycin or
oxazolidinon) be included in the empirical
regiment of clinically suspected necrotizing
infection?
Either clindamycin or linezolid should be included in the
empirical antibiotic regimen of NSTI (recommendation
1C).
Selection of antibiotics that inhibit toxin production
may be helpful, particularly in those patients who have
evidence of TSS, potentially present in patients who
have streptococcal and staphylococcal infections. Protein
cytotoxins play an important role in the pathogenesis of
various staphylococcal infections, and toxin production
should be considered when selecting an antimicrobial
agent for Gram-positive pathogens. Linezolid and clinda-
mycin play an important role because they may signifi-
cantly inhibit exotoxin production from Gram-positive
pathogens [117–119].
What is the optimal duration of antibiotic therapy
for necrotizing infections?
In the absence of definitive clinical trials, antibiotic
therapy should be administered until further debride-
ment is no longer necessary, the patient has improved
clinically, and fever has resolved for 48–72 h (recom-
mendation 1C).
Procalcitonin monitoring may be useful to guide
antimicrobial discontinuation (recommendation 2B).
There is no direct evidence about optimal duration of
antibiotic therapy, and the expert panel shares that anti-
microbial therapy should be administered until further de-
bridement is no longer necessary, the patient has improved
clinically, and fever has been resolved for 48–72 h.
Several controlled clinical studies have evaluated the
potential of the infection biomarker procalcitonin (PCT)
to improve the diagnostic work-up of patients with bac-
terial infections and its influence on decisions regarding
antibiotic therapy [120].
In order to develop a PCT ratio indicating successful
surgical intervention in patients with necrotizing infec-
tions, Friederichs et al. [121] designed a study of 38 pa-
tients treated with clinical signs of sepsis caused by a
NSTI. All patients received radical surgical treatment.
Serum levels of PCT and C-reactive protein were moni-
tored postoperatively. The ratio of day 1 to day 2 was
calculated. An eradication of the infectious focus was
successfully performed in 84% of patients, averaging 1.9
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operations (range 1–6) to achieve the elimination of the
infectious source. The PCT ratio was significantly higher
in the group of patients with successful surgical inter-
vention (1.665 versus 0.9, p < 0.001). A ratio higher than
the calculated cutoff of 1.14 indicated successful surgical
treatment with a sensitivity of 83.3% and a specificity of
71.4%. The positive predictive value was 75.8%, and the
negative predictive value was 80.0%.
The PCT ratio of postoperative day 1 to day 2 follow-
ing major surgical procedures for necrotizing infections
represented a valuable clinical tool indicating successful
surgical eradication of the infectious focus and corre-
lated with the successful elimination of the infectious
source and clinical recovery.
What is the treatment of Fournier’s gangrene?
Treatment of Fournier’s gangrene includes prompt
appropriate antibiotic therapy, hemodynamic sup-
port, and early debridement (recommendation 1C).
Early and extensive initial surgical debridement in
Fournier’s gangrene patients improves survival (rec-
ommendation 1C).
We suggest consideration for fecal diversion—ei-
ther by colostomy, fecal tube system with or without
negative pressure therapy—in cases of Fournier’s
gangrene with fecal contamination (recommendation
2C).
Fournier’s gangrene (FG) is a severe type of NSTI in-
volving the genital area and or perineum. It was initially
described by Baurinne in 1764 and is named after Jean
Alfred Fournier, a French dermatologist who in 1883 de-
scribed it. Due to the complexity of fascial planes, the
infection may extend up to the abdominal wall, down
into the thigh areas, into the perirectal and gluteal
spaces, and, occasionally, into the retroperitoneum. Ad-
vanced FG can extend through the fascial planes ascend-
ing as high as the torso and descending to the thighs.
The perineal fascia, Colles’ fascia, is continuous with
Scarpa’s fascia of the anterior abdominal wall and Buck
and Dartos’ fascia of the penis and scrotum. Testicular
involvement is rare, and this has been attributed to their
non-perineal blood supply. It has a mortality rate that
approaches 20–50% in many contemporary series [122–
124]. The origin of the infection is identifiable in the
majority of cases and is predominantly from anorectal,
genito-urinary, or local cutaneous sources [125]. The ag-
gressive nature of the infection requires early recogni-
tion and immediate surgical intervention.
Diagnosis is based on clinical signs and physical exam-
ination. Including cutaneous manifestations, erythema,
subcutaneous crepitations, patches of gangrene, a pres-
ence of potential portal of entry, foul smell, purulence
and/or wound discharge, and tenderness to palpitation.
Imaging, including conventional radiology, US, CT, and
MRI may be used to confirm clinical suspicions and to
help in identifying the extent of the soft-tissue involve-
ment, particularly in the perirectal and retroperitoneal
planes.
Fournier’s Gangrene Severity Index (FGSI) is a stand-
ard score for predicting outcome in patients with FG
and is obtained from a combination of physiological pa-
rameters at admission including temperature, heart rate,
respiration rate, sodium, potassium, creatinine, leuko-
cytes, hematocrit, and bicarbonate. A FGSI score above
9 has been demonstrated to be sensitive and specific as a
mortality predictor in patients with Fournier’s gangrene
[126, 127].
Surgical debridement must be early and aggressive to
halt progression of infection. Cultures of infected fluid
and tissues should be obtained during the initial surgical
debridement and the results used to tailor specific anti-
biotic management. Radical surgical debridement of the
entire affected area should be performed, continuing the
debridement into the healthy-looking tissue [128, 129].
In the setting of FG, diverting colostomy has been
demonstrated to improve outcomes. It helps in decreas-
ing sepsis by minimizing bacterial load in the perineal
wound, thus controlling infection [130]. Diverting colos-
tomy does not eliminate the necessity of multiple de-
bridements, nor reduces the number of these procedures
[131]. Diverting colostomy should be avoided as much
as possible mainly when there are other methods to
avoid wound contamination. Recently, rectal diversion
devices have been marketed. They are silicone tubes de-
signed to divert fecal matter in patients with diarrhea,
local burns, or skin ulcers. The devices protect the
wounds from fecal contamination and reduce, in the
same way a colostomy does, both the risk of skin break-
down and repeated inoculation with colonic microbial
flora. Fecal diversion tubes can be used in combination
with negative pressure wound therapy (NPWT) for ef-
fective isolation of the wound from fecal contamination.
Estrada et al. showed that this was an effective way for
fecal diversion and constitutes an attractive alternative
to colostomy [132].
What is the role of negative pressure wound
therapy in soft-tissue infections and necrotizing
fasciitis?
We suggest to consider negative pressure wound
therapy (NPWT) for wound care after complete re-
moval of necrosis in necrotizing infections (recom-
mendation 1C).
The rapidly spreading infection followed by aggressive
surgical intervention and repeated debridements creates
challenges for wound management. NPWT refers to
wound dressing systems that continuously or intermit-
tently apply sub-atmospheric pressure to the surface of a
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wound. NPWT has become a popular treatment modal-
ity for the management of many acute and chronic
wounds. Sub-atmospheric pressure has multiple benefi-
cial effects on wound healing in animal models. Animal
and human studies have shown that sub-atmospheric
pressure improves the local wound environment through
both direct and indirect effects; these effects accelerate
healing and reduce the time to wound closure [133].
In the setting of necrotizing infections once the necro-
sis is removed, NPWT can help wound healing physiolo-
gically. The negative pressure leads to an increased
blood supply, increasing tissue perfusion, reducing
edema, absorbing fluids and exudates, inhibiting infec-
tion, and finally drying the wound and thus the migra-
tion of inflammatory cells into the wound. Additionally,
it promotes and accelerates the formation of granulation
tissue by the removal of bacterial contamination and
exudates.
Although evidence of promising results with NPWT is
increasing in other fields [134–143], in NSTIs, the clin-
ical evidence of its superiority over conventional wound
dressing techniques for all wound types has not been
proven [144, 145].
A systematic review of PubMed and Cochrane Library
databases for randomized, controlled trials (RCTs) of
NPWT for the treatment of acute or chronic wounds was
published in 2011, which did not find clear evidence of a
beneficial effect of NPWT compared with conventional
treatment [146]. However, much evidence of a positive ef-
fect of NPWT on wound in general has been published
since and the 2011 systematic review is outdated.
What is the treatment of infected meshes?
Respect prevention strategies to avoid surgical site in-
fection and prosthetic contamination (recommenda-
tion 1A).
We suggest avoidance of mesh contamination fol-
lowing incisional SSI by an early and adequate local
source control as well as antibiotic treatment (recom-
mendation 1C).
In chronic sinuses and infected meshes, we suggest a
complete surgical removal of the mesh which remains
the only way to eradicate infection (recommendation
1C).
No clear recommendations on the benefit of bio-
logic versus synthetic mesh in potentially contami-
nated fields can be proposed (recommendations 1C).
Hernia repair is one of the most common surgical
procedures performed globally. Mesh infection, al-
though infrequent, is a devastating complication of
mesh hernioplasties, and for this reason, a prevention
strategy is essential. Currently, several types of pros-
thetic mesh are widely used for repairing abdominal
wall defects; however, there is no single universal
ideal mesh. Synthetic meshes are easy to handle and
well tolerated; however, they can be potentially associ-
ated with infection when bacteria adhere to the syn-
thetic material leading to chronic infection. Mesh
infection is a challenging complication of abdominal
wall defect repairs [147–149].
Polypropylene remains the most commonly used mater-
ial for hernia repairs. Synthetic meshes consisting of large
pore meshes are more resistant to infection than the firm,
smaller pore meshes. Although biological meshes cost
more than synthetic meshes and the long-term durability
may be less favorable [150, 151], they can confer protect-
ive factors such as resistance to infection and high bio-
compatibility when implanted [148].
In order to evaluate the risk factors for mesh-related
infections after surgical hernia repair, a systematic search
performed in PubMed and Scopus databases was pub-
lished in 2011 [152]. The crude mesh infection rate was
5%. Statistically significant risk factors were smoking
(RR = 1.36 [95% CI 1.07, 1.73]; 1171 hernioplasties),
American Society of Anesthesiologists (ASA) score ≥ 3
(RR = 1.40 [1.15, 1.70]; 1682 hernioplasties), and emer-
gency operation (RR = 2.46 [1.56, 3.91]; 1561 hernioplas-
ties). Also, mesh infections were significantly correlated
with patient age (weighted mean difference [WMD] =
2.63 [0.22, 5.04]; 2364 hernioplasties), ASA score
(WMD = 0.23 [0.08, 0.38]; 1682 hernioplasties), and the
duration of the hernioplasty (WMD = 44.92 [25.66,
64.18]; 833 hernioplasties). A trend toward higher mesh
infection rates was observed in obese patients (RR = 1.41
[0.94, 2.11]; 2243 hernioplasties) and in patients oper-
ated on by a resident (in contrast to a consultant; RR =
1.18 [0.99, 1.40]; 982 hernioplasties). Mesh infections
usually resulted in mesh removal, and Staphylococcus
spp., Enterococcus spp., and Gram-negative bacteria were
the germs commonly isolated in the specimen.
In 2017, a retrospective review of all patients who
underwent abdominal wall hernia repair from January
2004 to May 2014 at a tertiary center was published
[153]. From 3470 cases of abdominal wall hernia repair,
66 cases (1.9%) of mesh infection were reported, and 48
of these patients (72.7%) required mesh explantation.
Steroid or immunosuppressive drugs use (odds ratio
[OR] 2.22; CI 1.16 to 3.95), urgent repair (OR 5.06; CI
2.21 to 8.60), and postoperative surgical site infection
(OR 2.9; CI 1.55 to 4.10) were predictive of mesh infec-
tion. Independent predictors of mesh explantation were
type of mesh (OR 3.13; CI 1.71 to 5.21), onlay position
(OR 3.51; CI 1.23 to 6.12), and associated enterotomy in
the same procedure (OR 5.17; CI 2.05 to 7.12).
The pathogenesis of mesh infection is a complex
process involving many factors including, but not lim-
ited to, bacterial virulence, surface physicochemical
properties of the prosthetic material, and alterations in
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host defense mechanisms. The result of this interaction
is the formation of the bacterial biofilm. Embedded in
self-secreted extracellular polymeric substances, biofilm
can provide bacteria an effective barrier against host
immune cells and antibiotics [154–156]. Early antibi-
otics and mechanical scrubbing or irrigation to remove
the biofilm before it is consolidated are both important.
Mesh infections should be distinguished from super-
ficial incisional SSIs. They occur in the early postop-
erative period and are not influenced by mesh
implantation but can cause the infection of the mesh.
The diagnosis of wound infection is clinical, with typ-
ical symptoms of localized inflammation and pain at
the incision site. Patients with deep mesh infections
may present with signs of local inflammation. How-
ever, more frequently, deep mesh infections tend to
be indolent and present chronic signs and symptoms.
They may be initially underestimated.
The management of mesh-site infections is challenging
and always requires an individualized approach combining
medical and surgical approaches. Clinical trials have dem-
onstrated that in certain instances, non-operative strat-
egies with conservative (non-surgical) management have
been successful for salvaging a mesh [157]. If conservative
treatment fails, complete surgical removal of the mesh is
suggested to reduce the risk of infection recurrence or se-
vere complications, such as visceral adhesions and fistulae.
A conservative surgical approach including abscess drain-
age, sinus excision, or partial mesh excision can fail and
may result in recurrent mesh infections.
After removing the infected mesh, the intra-operative
options are (a) no implant of a new mesh, (b)
re-implantation of a new synthetic light-weight, macro-
porous mesh, and (c) replacement of the infected syn-
thetic by a biological mesh [158, 159]. A critical issue in
the repair of contaminated abdominal wall defects is the
dilemma of choosing between synthetic material, with its
presumed risk of surgical site complications, and bio-
logic material, a costly alternative with questionable dur-
ability. In 2016, Atema et al. published a systematic
review and meta-analysis of the repair of potentially con-
taminated and contaminated abdominal wall defects
[160]. Thirty-two studies published between January
1990 and June 2015 on repair of (potentially) contami-
nated hernias with ≥ 25 patients were reviewed. Fifteen
studies solely described hernia repair with biologic mesh,
6 non-absorbable synthetic meshes, and 11 described
various techniques. Studies reporting direct and pro-
spective comparison of synthetic versus biological mesh
in a cohort were not found. Surgical site complications
and hernia recurrence rates were evaluated per degree of
contamination and mesh type by calculating pooled pro-
portions. In potentially contaminated hernias (CDC
wound class 2), no benefit of biologic over synthetic
mesh was found with comparable surgical site complica-
tion rates and a hernia recurrence rate of 9% for biologic
and 9% for synthetic repair. In contaminated hernias
(CDC wound class 3 and 4), most reports were on bio-
logic mesh repair, showing high rates of surgical site
complications and a hernia recurrence rate of 30%. Re-
currence rates in contaminated hernias depended on
whether primary fascial closure was achieved, or the re-
pair with biologic mesh was bridging. Biologic mesh sub-
lay repair with primary fascial closure showed lower
recurrence rates than bridging repairs. Non-cross-linked
biologic mesh can be used in contaminated hernia with-
out mesh infection and subsequent need for mesh ex-
plantation. As only one study on synthetic repair of
contaminated hernias was available in literature, no rec-
ommendation can be given on the use of synthetic mesh
in this setting [161].
Conclusions
SSTIs encompass a variety of pathological conditions
ranging from simple superficial infections to severe nec-
rotizing infections. The multifaceted nature of these in-
fections has led to a collaboration among general and
emergency surgeons, intensivists, and infectious diseases
specialists, who have shared these clinical practice
recommendations.
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